Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 4/20 | 0.71 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.71 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.71 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.71 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.71 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.71 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11702314 | 0.89 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14696641 | 0.89 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1938937 | 0.85 | GRIN2D (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL25382017 | 0.85 | GRIN2D (0.60) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19628848 | 0.85 | GRIN2D (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL292537 | 0.84 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL6902613 | 0.84 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24105950 | 0.84 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL10413669 | 0.84 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL11252025 | 0.84 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013077-B2 | Polymerizing a cage-type silsesquioxane compound having unsaturated substituents with a heat resistant unsaturated siloxane or silazane, or an acetylenic compound; curing on a substrate; uniform thickness, excellent dielectric constant and tensile strength | FUJIFILM CORPORATION (JP) | 2011-09-06 | — | — | US | claimed |
| CN-116355646-B | Method for synthesizing high-energy-density heat-absorbing aviation fuel by one-step hydrogenation conversion of polycyclic aromatic hydrocarbon | 天津大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-116355646-A | Method for synthesizing high-energy-density heat-absorbing aviation fuel by one-step hydrogenation conversion of polycyclic aromatic hydrocarbon | 天津大学 | 2023-06-30 | — | — | CN | disclosed |
| WO-2023073222-A1 | INHIBITORS OF VIRAL HELICASES BINDING TO A NOVEL ALLOSTERIC BINDING SITE | EISBACH BIO GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-2331495-B1 | PROCESS FOR MANUFACTURING ADAMANTANE DERIVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO KGAA (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8796491-B2 | Process for manufacturing adamantane derivatives with high yield | MERZ PHARMA GMBH & CO. KGAA (DE) | 2014-08-05 | — | — | US | disclosed |
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-10-27 | — | — | US | disclosed |
| US-8013077-B2 | Polymerizing a cage-type silsesquioxane compound having unsaturated substituents with a heat resistant unsaturated siloxane or silazane, or an acetylenic compound; curing on a substrate; uniform thickness, excellent dielectric constant and tensile strength | FUJIFILM CORPORATION (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20080213492-A1 | INSULATING FILM FORMING COMPOSITION AND PRODUCTION METHOD OF INSULATING FILM | FUJIFILM CORPORATION (JP) | 2008-09-04 | — | — | US | disclosed |
| US-4849565-A | 1,3-diethynyladamantane and methods of polymerization thereof | BAUM KURT (US) | 1989-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263900-A1 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD | BACE1, BACE2, APP | GRIN2D 1299/4885GRIN3B 1154/4885GRIN1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.